Literature DB >> 9366322

The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms.

W M Murphy1, I Rivera-Ramirez, C A Medina, N J Wright, Z Wajsman.   

Abstract

PURPOSE: Tests to detect recurrent bladder neoplasms are limited and none is consistently accurate. Recent studies suggest that the bladder tumor antigen (BTA) test, an agglutination reaction for basement membrane complexes, is superior to voided urine cytology in clinical practice. We compared BTA and voided urine cytology to bladder washings and cystoscopy, emphasizing diagnostic yield among patients with causes of basement membrane complexes other than bladder cancer.
MATERIALS AND METHODS: Random voided urine specimens from 67 patients with a history of bladder neoplasms were collected before cystoscopy and bladder washing. Urine also was obtained from 34 patients with inflammatory bladder conditions including 5 with a history of prostate cancer. Each urine was tested for BTA according to a commercial kit. Positive results were indicated by yellow on a test pad. Blinded to all other results, each urine and each bladder washing were examined microscopically, and a positive test had malignant/suspicious cells. Bladder biopsies were performed when endoscopic lesions were seen. Specimens were grouped into 4 categories: group 1--biopsy proved bladder neoplasm, group 2--history of bladder cancer but not biopsy proved, group 3--history of prostate cancer and group 4--no history of urological cancer.
RESULTS: Voided urine cytology was positive in 54% of specimens from patients with biopsy proved bladder neoplasms compared to 29% for BTA. Relative yield for voided urine cytology versus BTA was not changed if all group 2 cases having a positive bladder washing and positive cystoscopy were assumed to have bladder cancer, nor was relative yield altered by subsequent short-term followup. Of voided urine specimens 14% from group 1 patients and 41% from group 2 patients had scant cells. Overall diagnostic yield was superior for bladder washing. False-positive BTA occurred in 7 of 34 patients with no history of urological or prostate cancer. There were no false-positive voided urine cytology interpretations in these groups.
CONCLUSIONS: BTA is not superior to voided urine cytology in detecting bladder neoplasms and may be limited by false-positive reactions in patients with other causes of basement membrane complexes in urine. Voided urine samples may be limited by high frequency of hypocellularity. Of 34 patients with a hypocellular urine specimen 4 had biopsy proved bladder cancer. Bladder washing yields best results but requires instrumentation. No test, including cystoscopy, is accurate always.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9366322     DOI: 10.1016/s0022-5347(01)68167-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  [Exfoliative urine cytology in the treatment of bladder cancer].

Authors:  S Tschirdewahn; F Vom Dorp; H Rübben; O W Hakenberg
Journal:  Urologe A       Date:  2011-03       Impact factor: 0.639

2.  Use of diagnostic categories in urinary cytology in comparison with the bladder tumour antigen (BTA) test in bladder cancer patients.

Authors:  M Takashi; U Schenck; K Kissel; H Leyh; U Treiber
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

Review 3.  Bladder tumor markers: need, nature and application. 1. Nucleus-based markers.

Authors:  M M Kirollos; S McDermott; R A Bradbrook
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1998

Review 4.  Bladder tumor markers: need, nature and application. 2. Tumor and tumor-associated antigens.

Authors:  M M Kirollos; S McDermott; R A Bradbrook
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1998

Review 5.  [Urinary cytology in cases of bladder cancer: a critical evaluation].

Authors:  P Rathert
Journal:  Urologe A       Date:  2003-03-26       Impact factor: 0.639

Review 6.  [Non-invasive urinary diagnosis of bladder cancer. What do we know?].

Authors:  I Kausch; A Böhle
Journal:  Urologe A       Date:  2003-04-11       Impact factor: 0.639

7.  Keratin 17 Is a Novel Cytologic Biomarker for Urothelial Carcinoma Diagnosis.

Authors:  Sruthi Babu; Nam W Kim; Maoxin Wu; Ina Chan; Luisa F Escobar-Hoyos; Kenneth R Shroyer
Journal:  Am J Clin Pathol       Date:  2021-10-13       Impact factor: 5.400

8.  Urinary laminin-γ2 is a novel biomarker of non-muscle invasive urothelial carcinoma.

Authors:  Masayuki Kamada; Naohiko Koshikawa; Tomoko Minegishi; Chiaki Kawada; Takashi Karashima; Taro Shuin; Motoharu Seiki
Journal:  Cancer Sci       Date:  2015-11-06       Impact factor: 6.716

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.